Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page

Creutzfeldt–Jakob disease (CJD) is a fatal neurodegenerative disease in the transmissible spongiform encephalopathy group, caused by misfolded prions. Early symptoms include memory loss, behavioral changes, and coordination issues, progressing to dementia, involuntary movements, and coma. About 70% of patients die within a year. Most cases occur sporadically, while some are inherited via autosomal dominant mutations. Diagnosis uses tools like electroencephalograms, spinal taps, and real-time quaking-induced conversion assays. No cure exists; treatments such as opioids relieve pain, while clonazepam may help involuntary movements. CJD is distinct from mad cow disease and variant CJD.

Related Image Collections Add Image
Profiles
1 Image
We don't have any YouTube videos related to Creutzfeldt–Jakob disease yet.
We don't have any PDF documents related to Creutzfeldt–Jakob disease yet.
We don't have any Books related to Creutzfeldt–Jakob disease yet.

Signs and symptoms

The first symptom of CJD is usually rapidly progressive dementia, leading to memory loss, personality changes, and hallucinations. Myoclonus (jerky movements) typically occurs in 90% of cases, but may be absent at initial onset.26 Other frequently occurring features include anxiety, depression, paranoia, obsessive-compulsive symptoms, and psychosis.27 This is accompanied by physical problems such as speech impairment, balance and coordination dysfunction (ataxia), changes in gait, and rigid posture. In most people with CJD, these symptoms are accompanied by involuntary movements. Rarely, unusual symptoms like the alien limb phenomenon have been observed.28 The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks.29 Most affected people die six months after initial symptoms appear, often of pneumonia due to impaired coughing reflexes. About 15% of people with CJD survive for two or more years.30

The symptoms of CJD are caused by the progressive death of the brain's nerve cells, which are associated with the build-up of abnormal prion proteins forming in the brain. When brain tissue from a person with CJD is examined under a microscope, many tiny holes can be seen where the nerve cells have died. Parts of the brain may resemble a sponge where the prions were infecting the areas of the brain.31

Cause

CJD is a type of transmissible spongiform encephalopathy (TSE), which are caused by prions.32 Prions are misfolded proteins that occur in the neurons of the central nervous system (CNS). The CJD prion is dangerous because it promotes refolding of cellular prion proteins into the diseased state.33 The number of misfolded protein molecules will increase exponentially and the process leads to a large quantity of insoluble proteins in affected cells. This mass of misfolded proteins disrupts neuronal cell function and causes cell death. Mutations in the gene for the prion protein can cause a misfolding of the dominantly alpha helical regions into beta pleated sheets. This change in conformation disables the ability of the protein to undergo digestion. Once the prion is transmitted, the defective proteins invade the brain and induce other prion protein molecules to misfold in a self-sustaining feedback loop. These neurodegenerative diseases are commonly called prion diseases.34

PrPC, large fibril cellular proteins, are misfolded by what current research suggests are small, highly neurotoxic oligomeric aggregates, known as PrPSc, which interact with cell surfaces to disrupt neuronal function.35 The binding of prion oligomers to normal prion protein on neurons may trigger toxic signals similar to how oligomeric β-amyloid causes synaptic damage in Alzheimer’s disease.36 Different conformations of PrPSc (often termed prion “strains”) are thought to cause the distinct subtypes of prion disease, explaining variations in clinical features and progression.37 They are thought to affect signaling processes, damaging neurons and resulting in degeneration that causes the spongiform appearance in the affected brain.38 Other forms of TSEs that are found in humans are Gerstmann–Sträussler–Scheinker syndrome, fatal familial insomnia, and kuru, as well as the variably protease-sensitive prionopathy and familial spongiform encephalopathy transmissible spongiform encephalopathy. Susceptibility and disease phenotype are influenced by a common polymorphism at codon 129 of the PRNP gene (methionine/valine). Notably, individuals homozygous at codon 129 are over-represented in sporadic CJD cases and tend to have shorter incubation periods.39

Transmission

The defective protein can be transmitted by contaminated harvested human brain products, corneal grafts,40 dural grafts,41 or electrode42 implants and pituitary human growth hormone, which has been replaced by recombinant human growth hormone that poses no such risk.43

It can be familial (fCJD) or it may appear without clear risk factors (sporadic form: sCJD). In the familial form, a mutation has occurred in the gene for PrP, PRNP, in that family. All types of CJD are transmissible irrespective of how they occur in the person.44

It is thought that humans can contract the variant form of the disease by eating food from animals infected with bovine spongiform encephalopathy (BSE), the bovine form of TSE, also known as mad cow disease. However, it can also cause sCJD in some cases.4546

Cannibalism has also been implicated as a transmission mechanism for abnormal prions, causing the disease known as kuru, once found primarily among women and children of the Fore people in Papua New Guinea, who previously engaged in funerary cannibalism.47 While the men of the tribe ate the muscle tissue of the deceased, women and children consumed other parts, such as the brain, and were more likely than men to contract kuru from infected tissue.48

Prions, the infectious agent of CJD, may not be inactivated by means of routine surgical instrument sterilization procedures. The World Health Organization and the US Centers for Disease Control and Prevention recommend that instrumentation used in such cases be immediately destroyed after use; short of destruction, it is recommended that heat and chemical decontamination be used in combination to process instruments that come in contact with high-infectivity tissues. Thermal depolymerization also destroys prions in infected organic and inorganic matter, since the process chemically attacks protein at the molecular level, although more effective and practical methods involve destruction by combinations of detergents and enzymes similar to biological washing powders.49

Genetics

People can also develop CJD because they carry a mutation of the gene that codes for the prion protein (PRNP), located on chromosome 202p12-pter. This occurs in only 10–15% of all CJD cases.50 In sporadic cases, the misfolding of the prion protein is a process that is hypothesized to occur as a result of the effects of aging on cellular machinery, explaining why the disease often appears later in life.5152 An EU study determined that "87% of cases were sporadic, 8% genetic, 5% iatrogenic and less than 1% variant."53

Diagnosis

Testing for CJD has historically been problematic, due to nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when it is also found with the characteristic medical signs and symptoms such as involuntary muscle jerking,54 difficulty with coordination/balance and walking, and visual disturbances.55 Further testing can support the diagnosis and may include:

  • Electroencephalography – may have characteristic generalized periodic sharp wave pattern. Periodic sharp wave complexes develop in half of the people with sporadic CJD, particularly in the later stages.56
  • Cerebrospinal fluid (CSF) analysis for elevated levels of 14-3-3 protein and tau protein could be supportive in the diagnosis of sCJD. The two proteins are released into the CSF by damaged nerve cells. Increased levels of tau or 14-3-3 proteins are seen in 90% of prion diseases. The markers have a specificity of 95% in clinical symptoms suggestive of CJD, but specificity is 70% in other less characteristic cases.57 14-3-3 and tau proteins may also be elevated in the CSF after ischemic strokes, inflammatory brain diseases, or seizures.58 The protein markers are also less specific in early CJD, genetic CJD or the bovine variant.59 However, a positive result should not be regarded as sufficient for the diagnosis.606162 The real-time quaking-induced conversion (RT-QuIC) assay, which amplifies misfolded PrP^Sc, now plays a central role in CJD diagnosis. Second-generation RT-QuIC on cerebrospinal fluid has sensitivity in the 90–97% range and ~100% specificity in sporadic CJD,63 far superior to earlier CSF tests. A positive RT-QuIC (on CSF or other tissues) is now included as a criterion for probable CJD in many national surveillance center.64 Studies have shown RT-QuIC can also be done on olfactory mucosa swabs obtained via nasal brushing and on skin biopsies, with high diagnostic accuracy (reported sensitivities ~90–100%).65
  • MRI with diffusion weighted inversion (DWI) and fluid-attenuated inversion recovery (FLAIR) shows a high signal intensity in certain parts of the cortex (a cortical ribboning appearance), the basal ganglia, and the thalami.66 The most common presenting patterns are simultaneous involvement of the cortex and striatum (60% of cases), cortical involvement without the striatum (30%), thalamus (21%), cerebellum (8%) and striatum without cortical involvement (7%). In populations with a rapidly progressive dementia (early in the disease process), MRI has a sensitivity of 91% and specificity of 97% for diagnosing CJD.67 The MRI changes characteristic of CJD may also be seen in the immediate aftermath (hours after the event) of autoimmune encephalitis or focal seizures.68

In recent years, studies have shown that the tumour marker neuron-specific enolase (NSE) is often elevated in CJD cases; however, its diagnostic utility is seen primarily when combined with a test for the 14-3-3 protein.69 As of 2010, screening tests to identify infected asymptomatic individuals, such as blood donors, are not yet available, though methods have been proposed and evaluated.70

Imaging

Imaging of the brain may be performed during medical evaluation, both to rule out other causes and to obtain supportive evidence for diagnosis. Imaging findings are variable in their appearance, and also variable in sensitivity and specificity.71 While imaging plays a lesser role in diagnosis of CJD,72 characteristic findings on brain MRI in some cases may precede onset of clinical manifestations.73

Brain MRI is the most useful imaging modality for changes related to CJD. Of the MRI sequences, diffuse-weighted imaging sequences are most sensitive.74 Characteristic findings are as follows:

  • Focal or diffuse diffusion-restriction involving the cerebral cortex or basal ganglia. The most characteristic and striking cortical abnormality has been called "cortical ribboning" or "cortical ribbon sign" due to hyperintensities resembling ribbons appearing in the cortex on MRI.75 The involvement of the thalamus can be found in sCJD, is even stronger and constant in vCJD.76
  • Varying degree of symmetric T2 hyperintense signal changes in the basal ganglia (i.e., caudate and putamen), and to a lesser extent globus pallidus and occipital cortex.77

Brain FDG PET-CT tends to be markedly abnormal, and is increasingly used in the investigation of dementias.

  • Patients with CJD will normally have hypometabolism on FDG PET.78

Histopathology

Testing of tissue remains the most definitive way of confirming the diagnosis of CJD, although even biopsy is not always conclusive.79

In one-third of people with sporadic CJD, deposits of "prion protein (scrapie)", PrPSc, can be found in the skeletal muscle or the spleen.80 Diagnosis of vCJD can be supported by biopsy of the tonsils, which harbor significant amounts of PrPSc; however, biopsy of brain tissue is the definitive diagnostic test for all other forms of prion disease. Due to its invasiveness, biopsy will not be done if clinical suspicion is sufficiently high or low. A negative biopsy does not rule out CJD, since it may predominate in a specific part of the brain.81

The classic histologic appearance is spongiform change in the gray matter: the presence of many round vacuoles from one to 50 micrometers in the neuropil, in all six cortical layers in the cerebral cortex or with diffuse involvement of the cerebellar molecular layer.82 These vacuoles appear glassy or eosinophilic and may coalesce. Neuronal loss and gliosis are also seen.83 Plaques of amyloid-like material can be seen in the neocortex in some cases of CJD.84

However, extra-neuronal vacuolization can also be seen in other disease states. Diffuse cortical vacuolization occurs in Alzheimer's disease, and superficial cortical vacuolization occurs in ischemia and frontotemporal dementia. These vacuoles appear clear and punched-out. Larger vacuoles encircling neurons, vessels, and glia are a possible processing artifact.85

Classification

Types of CJD include:86

  • Sporadic (sCJD), caused by the spontaneous misfolding of prion-protein in an individual.87 This accounts for 85% of cases of CJD.88 Sporadic CJD is can be further sub-classified by molecular profile into subtypes (MM1, MV2, etc.), which correlate with certain clinical-pathologic features.89
    • MM1 / MV1 Subtype:
      • Clinical Features: Accounts for approximately 75% of sCJD cases. Characterized by rapidly progressive dementia, myoclonus, and typical EEG findings.
      • Neuropathology: Synaptic-type PrP^Sc deposition predominantly in the cerebral cortex. Spongiform changes are widespread, with significant neuronal loss and gliosis.9091
    • MM2 Subtype:
      • MM2C (Cortical): Presents with a more prolonged disease course and prominent cortical involvement. Neuropathology reveals PrP^Sc deposits in the cortex with less spongiform change compared to MM1.
      • MM2T (Thalamic): Rare; characterized by predominant thalamic involvement, leading to sleep disturbances and autonomic dysfunction. Neuropathology shows significant PrP^Sc deposition and neuronal loss in the thalamus.92
    • VV1 Subtype:
      • Clinical Features: Rare; presents at a younger age with a slower disease progression.93
      • Neuropathology: Predominant cortical involvement with synaptic-type PrP^Sc deposition.94
    • VV2 Subtype:
      • Clinical Features: Second most common subtype. Patients often present with ataxia and other cerebellar signs.
      • Neuropathology: Significant PrP^Sc deposition in the cerebellum and basal ganglia, with prominent spongiform changes and neuronal loss.95
  • Familial (fCJD), caused by an inherited mutation in the prion-protein gene.96 This accounts for the majority of the other 15% of cases of CJD.97
  • Acquired CJD, caused by contamination with tissue from an infected person, usually as the result of a medical procedure (iatrogenic CJD). Medical procedures that are associated with the spread of this form of CJD include blood transfusion from the infected person, use of human-derived pituitary growth hormones, gonadotropin hormone therapy, and corneal and meningeal transplants.9899100 Variant Creutzfeldt–Jakob disease (vCJD) is a type of acquired CJD potentially acquired from bovine spongiform encephalopathy or caused by consuming food contaminated with prions.101102 Sporadic CJD, while transmissible through tissue transplants, may not be transmitted through blood transfusion.103
Clinical and pathologic characteristics104
CharacteristicClassic CJDVariant CJD
Median age at death68 years28 years
Median duration of illness4–5 months13–14 months
Clinical signs and symptomsDementia; early neurologic signsProminent psychiatric/behavioral symptoms; painful dysesthesias; delayed neurologic signs
Periodic sharp waves on electroencephalogramOften presentOften absent
Signal hyperintensity in the caudate nucleus and putamen on diffusion-weighted and FLAIR MRIOften presentOften absent
Pulvinar sign-bilateral high signal intensities on axial FLAIR MRI. Also posterior thalamic involvement on sagittal T2 sequencesNot reportedPresent in >75% of cases
Immunohistochemical analysis of brain tissueVariable accumulation.Marked accumulation of protease-resistant prion protein
Presence of agent in lymphoid tissueNot readily detectedReadily detected
Increased glycoform ratio on immunoblot analysis of protease-resistant prion proteinNot reportedMarked accumulation of protease-resistant prion protein
Presence of amyloid plaques in brain tissueMay be presentMay be present

Treatment

As of 2025, there is no cure or effective treatment for CJD.105 Some of the symptoms like twitching can be managed, but otherwise treatment is palliative care.106 Psychiatric symptoms like anxiety and depression can be treated with sedatives and antidepressants. Myoclonic jerks can be handled with clonazepam or sodium valproate. Opiates can help in pain.107 Seizures are very uncommon but can nevertheless be treated with antiepileptic drugs.108

In 2022, results of an early-stage trial of PRN100, a monoclonal antibody against PrP, were reported: the drug appeared safe and reached the brain, but treated patients did not show clearly improved survival compared to historical controls. While not curative, this trial demonstrated the feasibility of immunotherapy for prion disease.109

Prognosis

Life expectancy is greatly reduced for people with Creutzfeldt–Jakob disease and the average is less than 6 months. As of 1981, no one was known to have lived longer than 2.5 years after the onset of CJD symptoms.110 One of the world's longest survivors of vCJD was Jonathan Simms, a Northern Irish man who lived for 10 years after his diagnosis and received experimental treatment with pentosan polysulphate. Simms died in 2011.111

Epidemiology

The CDC monitors the occurrence of CJD in the United States through periodic reviews of national mortality data. According to the CDC:112113114

  • CJD occurs worldwide at roughly 1–1.5 cases per million people per year. Recent surveillance reports indicate a slight increase in recorded incidence in many countries over time. For example, a study made in 2020 noted that sporadic CJD incidence in the U.K. rose from 1990 to 2018, and several other countries also reported increases in CJD cases in the 2000s.115
  • On the basis of mortality surveillance from 1979 to 1994, the annual incidence of CJD remained stable at approximately 1 case per million people in the United States.
  • In the United States, CJD deaths among people younger than 30 years of age are extremely rare (fewer than five deaths per billion per year).
  • The disease is found most frequently in people 55–65 years of age, but cases can occur in people older than 90 years and younger than 55 years of age.
  • In more than 85% of cases, the duration of CJD is less than one year (median: four months) after the onset of symptoms.

Further information from the CDC:116

  • Risk of developing CJD increases with age.
  • CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017.
  • Approximately 85% of CJD cases are sporadic and 10–15% of CJD cases are due to inherited mutations of the prion protein gene.
  • CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017.

Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months.117

According to a 2020 systematic review on the international epidemiology of CJD:118

  • Surveillance studies from 2005 and later show the estimated global incidence is 1–2 cases per million population per year.
  • Sporadic CJD (sCJD) incidence increased from the years 1990–2018 in the UK.
  • Probable or definite sCJD deaths also increased from the years 1996–2018 in twelve additional countries.
  • CJD incidence is greatest in those over the age of 55 years old, with an average age of 67 years old.

The intensity of CJD surveillance increases the number of reported cases, often in countries where CJD epidemics have occurred in the past and where surveillance resources are greatest.119 An increase in surveillance and reporting of CJD is most likely in response to BSE and vCJD.120 Possible factors contributing to an increase of CJD incidence are an aging population, population increase, clinician awareness, and more accurate diagnostic methods. Since CJD symptoms are similar to other neurological conditions, it is also possible that CJD is mistaken for stroke, acute nephropathy, general dementia, and hyperparathyroidism.121

History

The disease was first described by German neurologist Hans Gerhard Creutzfeldt in 1920 and shortly afterward by Alfons Maria Jakob, giving it the name Creutzfeldt–Jakob disease. Some of the clinical findings described in their first papers do not match current criteria for Creutzfeldt–Jakob disease, and it has been speculated that at least two of the people in initial studies had a different ailment.122 An early description of familial CJD stems from the German psychiatrist and neurologist Friedrich Meggendorfer (1880–1953).123124 A study published in 1997 counted more than 100 cases worldwide of transmissible CJD and new cases continued to appear at the time.125

The first report of suspected iatrogenic CJD was published in 1974. Animal experiments showed that corneas of infected animals could transmit CJD, and the causative agent spreads along visual pathways. A second case of CJD associated with a corneal transplant was reported without details. In 1977, CJD transmission caused by silver electrodes previously used in the brain of a person with CJD was first reported. Transmission occurred despite the decontamination of the electrodes with ethanol and formaldehyde. Retrospective studies identified four other cases likely of similar cause. The rate of transmission from a single contaminated instrument is unknown, although it is not 100%. In some cases, the exposure occurred weeks after the instruments were used on a person with CJD.126 In the 1980s it was discovered that Lyodura, a dura mater transplant product, was shown to transmit CJD from the donor to the recipient. This led to the product being banned in Canada but it was used in other countries such as Japan until 1993.127 A review article published in 1979 indicated that 25 dura mater cases had occurred by that date in Australia, Canada, Germany, Italy, Japan, New Zealand, Spain, the United Kingdom, and the United States.128

By 1985, a series of case reports in the United States showed that when injected, cadaver-extracted pituitary human growth hormone could transmit CJD to humans.129

In 1992, it was recognized that human gonadotropin administered by injection could also transmit CJD from person to person.130

Stanley B. Prusiner of the University of California, San Francisco (UCSF) was awarded the Nobel Prize in Physiology or Medicine in 1997 "for his discovery of Prions—a new biological principle of infection".131

Yale University neuropathologist Laura Manuelidis has challenged the prion protein (PrP) explanation for the disease. In January 2007, she and her colleagues reported that they had found a virus-like particle in naturally and experimentally infected animals. "The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid–protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions".132

Australia

Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.133

New Zealand

A case was reported in 1989 in a 25-year-old man from New Zealand, who also received dura mater transplant.134 Five New Zealanders have been confirmed to have died of the sporadic form of Creutzfeldt–Jakob disease (CJD) in 2012.135

United States

In 1988 there was a confirmed death from CJD of a person from Manchester, New Hampshire. Massachusetts General Hospital believed the person acquired the disease from a surgical instrument at a podiatrist's office. In 2007 Michael Homer, former Vice President of Netscape, had been experiencing consistent memory problems which led to his diagnosis.136 In August 2013 the British journalist Graham Usher died in New York of CJD.137

In September 2013, another person in Manchester was posthumously determined to have died of the disease. The person had undergone brain surgery at Catholic Medical Center three months before his death, and a surgical probe used in the procedure was subsequently reused in other operations. Public health officials identified thirteen people at three hospitals who may have been exposed to the disease through the contaminated probe but said the risk of anyone contracting CJD is "extremely low".138139140

In January 2015, former speaker of the Utah House of Representatives Rebecca D. Lockhart died of the disease within a few weeks of diagnosis.141 John Carroll, former editor of The Baltimore Sun and Los Angeles Times, died of CJD in Kentucky in June 2015, after having been diagnosed in January.142 American actress Barbara Tarbuck (General Hospital, American Horror Story) died of the disease on December 26, 2016.143 José Baselga, clinical oncologist having headed the AstraZeneca oncology division, died in Cerdanya, March 21, 2021, from CJD.144 In April 2024, a report was published regarding two hunters from the same lodge who, in 2022, were found to be afflicted with sporadic CJD after eating deer meat infected with chronic wasting disease (CWD), suggesting a potential link between CWD and CJD.145

Research

Diagnosis

  • In 2010, a team from New York described detection of PrPSc in sheep's blood, even when initially present at only one part in one hundred billion (10−11) in sheep's brain tissue. The method combines amplification with a novel technology called surround optical fiber immunoassay (SOFIA) and some specific antibodies against PrPSc. The technique allowed improved detection and testing time for PrPSc.146147
  • In 2014, a human study showed a nasal brushing method that can accurately detect PrP in the olfactory epithelial cells of people with CJD.148

Treatment

  • Pentosan polysulfate (PPS) may slow the progression of the disease, and may have contributed to the longer than expected survival of the seven people studied.149 The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that pentosan polysulfate is an effective treatment and suggests that further research in animal models is appropriate.150 A 2007 review of the treatment of 26 people with PPS finds no proof of efficacy because of the lack of accepted objective criteria, but it was unclear to the authors whether that was caused by PPS itself.151 In 2012 it was claimed that the lack of significant benefits has likely been caused because of the drug being administered very late in the disease in many patients.152
  • Use of RNA interference to slow the progression of scrapie has been studied in mice. The RNA blocks production of the protein that the CJD process transforms into prions.153154
  • Both amphotericin B and doxorubicin have been investigated as treatments for CJD, but as yet there is no strong evidence that either drug is effective in stopping the disease. Further study has been taken with other medical drugs, but none are effective. However, anticonvulsants and anxiolytic agents, such as valproate or a benzodiazepine, may be administered to relieve associated symptoms.155
  • Quinacrine, a medicine originally created for malaria, has been evaluated as a treatment for CJD. The efficacy of quinacrine was assessed in a rigorous clinical trial in the UK and the results were published in Lancet Neurology,156 and concluded that quinacrine had no measurable effect on the clinical course of CJD.
  • Astemizole, a medication approved for human use, has been found to have anti-prion activity and may lead to a treatment for Creutzfeldt–Jakob disease.157
  • A monoclonal antibody (code name PRN100) targeting the prion protein (PrP) was given to six people with Creutzfeldt–Jakob disease in an early-stage clinical trial conducted from 2018 to 2022. The treatment appeared to be well-tolerated and was able to access the brain, where it might have helped to clear PrPC. While the treated patients still showed progressive neurological decline, and while none of them survived longer than expected from the normal course of the disease, the scientists at University College London who conducted the study see these early-stage results as encouraging and suggest to conduct a larger study, ideally at the earliest possible intervention.158

See also

References

  1. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  2. "Creutzfeldt–Jakob Disease, Classic (CJD)". CDC. 2 October 2018. Retrieved 21 November 2018. https://www.cdc.gov/creutzfeldt-jakob/about/ ↩

  3. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  4. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  5. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  6. Creutzfeldt–Jakob disease @ Who Named It http://www.whonamedit.com/synd.cfm/696.html ↩

  7. "Creutzfeldt–Jakob Disease, Classic (CJD) | Prion Diseases | CDC". www.cdc.gov. 1 February 2019. Retrieved 17 June 2019. Classic CJD is a human prion disease https://www.cdc.gov/prions/cjd/index.html ↩

  8. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  9. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  10. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A (2015-11-01). "Creutzfeldt–Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy". Neurosurgical Focus. 39 (5): E2. doi:10.3171/2015.8.FOCUS15328. ISSN 1092-0684. PMID 26646926. https://doi.org/10.3171%2F2015.8.FOCUS15328 ↩

  11. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  12. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  13. Brandel J, Vlaciu M, Culeux A, Belondrade M, Grznarova K, Plu I, Levasseur M, Haik S (July 2, 2020). "Variant Creutzfeldt–Jakob Disease Diagnosed 7.5 Years after Occupational Exposure". New England Journal of Medicine. 383 (1): 83–85. doi:10.1056/NEJMc2000687. PMID 32609989. https://doi.org/10.1056%2FNEJMc2000687 ↩

  14. "Transfusion Handbook/ 5.4: Variant Creutzfeldt–Jakob disease (vCJD)". Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. 4 February 2014. Archived from the original on 2017-03-05. Retrieved 29 July 2021. https://www.transfusionguidelines.org/transfusion-handbook/5-adverse-effects-of-transfusion/5-4-variant-creutzfeldt-jakob-disease-vcjd ↩

  15. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  16. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  17. Green AJ (February 2019). "RT-QuIC: a new test for sporadic CJD". Practical Neurology. 19 (1): 49–55. doi:10.1136/practneurol-2018-001935. ISSN 1474-7766. PMC 6580883. PMID 30282760. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580883 ↩

  18. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  19. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  20. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  21. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  22. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  23. "About CJD | Creutzfeldt–Jakob Disease, Classic (CJD) | Prion Disease". CDC. 11 February 2015. Archived from the original on 8 August 2017. Retrieved 16 July 2017. https://www.cdc.gov/prions/cjd/about.html ↩

  24. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A (2015-11-01). "Creutzfeldt–Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy". Neurosurgical Focus. 39 (5): E2. doi:10.3171/2015.8.FOCUS15328. ISSN 1092-0684. PMID 26646926. https://doi.org/10.3171%2F2015.8.FOCUS15328 ↩

  25. "Creutzfeldt–Jakob Disease, Classic (CJD) | Prion Diseases". CDC. 6 February 2015. Archived from the original on 18 July 2017. Retrieved 16 July 2017. https://www.cdc.gov/prions/cjd/index.html ↩

  26. "A 49-Year-Old Man With Forgetfulness and Gait Impairment". reference.medscape.com/viewarticle/881806_3. Archived from the original on 2017-07-06. Retrieved 2017-07-09. https://web.archive.org/web/20170706181402/http://reference.medscape.com/viewarticle/881806_3 ↩

  27. Murray ED, Buttner N, Price BH. (2012) Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6th Edition. Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.) Butterworth Heinemann. April 12, 2012. ISBN 1437704344, 978-1437704341 /wiki/ISBN_(identifier) ↩

  28. Noor H, Baqai MH, Naveed H, Naveed T, Rehman SS, Aslam MS, Lakdawala FM, Memon WA, Rani S, Khan H, Imran A, Farooqui SK (2024-12-15). "Creutzfeldt-Jakob disease: A comprehensive review of current understanding and research". Journal of the Neurological Sciences. 467: 123293. doi:10.1016/j.jns.2024.123293. ISSN 0022-510X. PMID 39546829. https://www.sciencedirect.com/science/article/abs/pii/S0022510X24004295#:~:text=Creutzfeldt,27029 ↩

  29. Brown P, Cathala F, Castaigne P, Gajdusek DC (November 1986). "Creutzfeldt–Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases". Annals of Neurology. 20 (5): 597–602. doi:10.1002/ana.410200507. PMID 3539001. S2CID 7995631. /wiki/Doi_(identifier) ↩

  30. Gambetti P. "Creutzfeldt–Jakob Disease (CJD)". The Merck Manuals: Online Medical Library. Archived from the original on 2011-06-04. Retrieved 2011-06-04. http://www.merckmanuals.com/home/sec06/ch090/ch090b.html ↩

  31. Atalay FO, Tolunay S, Ozgun G, Bekar A, Zarifoglu M (2013). "Creutzfeldt–Jakob disease: report of four cases and review of the literature". Turkish Journal of Pathology. 31 (2): 148–152. doi:10.5146/tjpath.2013.01195. ISSN 1018-5615. PMID 24272930. https://doi.org/10.5146%2Ftjpath.2013.01195 ↩

  32. "Creutzfeldt–Jakob Disease, Classic (CJD) | Prion Diseases | CDC". www.cdc.gov. 1 February 2019. Retrieved 17 June 2019. Classic CJD is a human prion disease https://www.cdc.gov/prions/cjd/index.html ↩

  33. Clarke AR, Jackson GS, Collinge J (February 2001). "The molecular biology of prion propagation". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356 (1406): 185–95. doi:10.1098/rstb.2000.0764. PMC 1088424. PMID 11260799. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088424 ↩

  34. Geschwind MD (2015). "Prion Diseases". Continuum. 21 (6): 1612–1638. doi:10.1212/CON.0000000000000251. PMC 4879966. PMID 26633779. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879966 ↩

  35. Sigurdson CJ, Bartz JC, Glatzel M (2019-01-24). "Cellular and Molecular Mechanisms of Prion Disease". Annual Review of Pathology. 14: 497–516. doi:10.1146/annurev-pathmechdis-012418-013109. ISSN 1553-4014. PMC 9071098. PMID 30355150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071098 ↩

  36. Sigurdson CJ, Bartz JC, Glatzel M (2019-01-24). "Cellular and Molecular Mechanisms of Prion Disease". Annual Review of Pathology. 14: 497–516. doi:10.1146/annurev-pathmechdis-012418-013109. ISSN 1553-4014. PMC 9071098. PMID 30355150. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071098 ↩

  37. Benavente R, Morales R (2024-12-10). "Therapeutic perspectives for prion diseases in humans and animals". PLOS Pathogens. 20 (12): e1012676. doi:10.1371/journal.ppat.1012676. ISSN 1553-7374. PMC 11630594. PMID 39656691. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630594 ↩

  38. Sattar HA (2017). Fundamentals of Pathology. Pathoma.com. p. 189. ISBN 978-0-9832246-3-1. 978-0-9832246-3-1 ↩

  39. Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P (March 2021). "Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease". The Lancet. Neurology. 20 (3): 235–246. doi:10.1016/S1474-4422(20)30477-4. ISSN 1474-4465. PMC 8285036. PMID 33609480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285036 ↩

  40. Armitage WJ, Tullo AB, Ironside JW (October 2009). "Risk of Creutzfeldt–Jakob disease transmission by ocular surgery and tissue transplantation". Eye. 23 (10): 1926–30. doi:10.1038/eye.2008.381. PMID 19136921. https://doi.org/10.1038%2Feye.2008.381 ↩

  41. Esmonde T, Lueck CJ, Symon L, Duchen LW, Will RG (September 1993). "Creutzfeldt–Jakob disease and lyophilised dura mater grafts: report of two cases". Journal of Neurology, Neurosurgery, and Psychiatry. 56 (9): 999–1000. doi:10.1136/jnnp.56.9.999. PMC 489736. PMID 8410042. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489736 ↩

  42. Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, Gajdusek DC, Gibbs CJ (February 1977). "Danger of accidental person-to-person transmission of Creutzfeldt–Jakob disease by surgery". Lancet. 1 (8009): 478–9. doi:10.1016/s0140-6736(77)91958-4. PMID 65575. S2CID 26804024. /w/index.php?title=Franco_Regli&action=edit&redlink=1 ↩

  43. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG, Ladogana A, Pocchiari M, Leschek EW, Schonberger LB (June 2012). "Iatrogenic Creutzfeldt–Jakob disease, final assessment". Emerging Infectious Diseases. 18 (6): 901–7. doi:10.3201/eid1806.120116. PMC 3358170. PMID 22607808. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358170 ↩

  44. Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC (May 1994). "Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease". Annals of Neurology. 35 (5): 513–29. doi:10.1002/ana.410350504. PMID 8179297. S2CID 22496358. /wiki/Doi_(identifier) ↩

  45. "New form of BSE resembles sporadic CJD". CIDRAP. 19 February 2004. https://www.cidrap.umn.edu/news-perspective/2004/02/new-form-bse-resembles-sporadic-cjd ↩

  46. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (October 1996). "Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD". Nature. 383 (6602): 685–90. Bibcode:1996Natur.383..685C. doi:10.1038/383685a0. PMID 8878476. S2CID 4355186. /wiki/Bibcode_(identifier) ↩

  47. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP (June 2006). "Kuru in the 21st century--an acquired human prion disease with very long incubation periods". Lancet. 367 (9528): 2068–74. doi:10.1016/s0140-6736(06)68930-7. PMID 16798390. S2CID 11506094. /wiki/Doi_(identifier) ↩

  48. Liberski PP (2013). "Kuru: A Journey Back in Time from Papua New Guinea to the Neanderthals' Extinction". Pathogens. 2 (3): 472–505. doi:10.3390/pathogens2030472. PMC 4235695. PMID 25437203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235695 ↩

  49. Jackson GS, McKintosh E, Flechsig E, Prodromidou K, Hirsch P, Linehan J, Brandner S, Clarke AR, Weissmann C, Collinge J (March 2005). "An enzyme-detergent method for effective prion decontamination of surgical steel". The Journal of General Virology. 86 (Pt 3): 869–78. doi:10.1099/vir.0.80484-0. PMID 15722550. https://doi.org/10.1099%2Fvir.0.80484-0 ↩

  50. Wallesch CW, Förstl H, eds. (2012), "3.3 Demenz mit Lewy-Körperchen", Demenzen, Stuttgart: Georg Thieme Verlag, doi:10.1055/b-0034-22435, ISBN 978-3-13-136912-3, retrieved 2024-03-15 978-3-13-136912-3 ↩

  51. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  52. Ridley RM, Baker HF, Crow TJ (February 1986). "Transmissible and non-transmissible neurodegenerative disease: similarities in age of onset and genetics in relation to aetiology". Psychological Medicine. 16 (1): 199–207. doi:10.1017/s0033291700002634. PMID 3961045. S2CID 38449324. /wiki/Doi_(identifier) ↩

  53. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, de Silva R, D'Alessandro M, Delasnerie-Laupretre N, Zerr I, van Duijn C (June 1998). "Descriptive epidemiology of Creutzfeldt–Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD". Annals of Neurology. 43 (6): 763–7. doi:10.1002/ana.410430611. PMID 9629846. S2CID 13562215. /wiki/Doi_(identifier) ↩

  54. Sattar HA (2011). Fundamentals of Pathology. Chicago: Pathoma LLC. p. 187. ISBN 978-0-9832246-0-0. 978-0-9832246-0-0 ↩

  55. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  56. Mead S, Rudge P (April 2017). "CJD mimics and chameleons". Practical Neurology. 17 (2): 113–121. doi:10.1136/practneurol-2016-001571. PMC 5520355. PMID 28153848. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520355 ↩

  57. Zerr I (7 April 2022). "Laboratory Diagnosis of Creutzfeldt–Jakob Disease". New England Journal of Medicine. 386 (14): 1345–1350. doi:10.1056/NEJMra2119323. PMID 35388668. /wiki/Doi_(identifier) ↩

  58. Zerr I (7 April 2022). "Laboratory Diagnosis of Creutzfeldt–Jakob Disease". New England Journal of Medicine. 386 (14): 1345–1350. doi:10.1056/NEJMra2119323. PMID 35388668. /wiki/Doi_(identifier) ↩

  59. Zerr I (7 April 2022). "Laboratory Diagnosis of Creutzfeldt–Jakob Disease". New England Journal of Medicine. 386 (14): 1345–1350. doi:10.1056/NEJMra2119323. PMID 35388668. /wiki/Doi_(identifier) ↩

  60. Satoh J, Kurohara K, Yukitake M, Kuroda Y (1999). "The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture". European Neurology. 41 (4): 216–25. doi:10.1159/000008054. PMID 10343153. S2CID 21795464. /wiki/Doi_(identifier) ↩

  61. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL (June 2003). "Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease". Archives of Neurology. 60 (6): 813–6. doi:10.1001/archneur.60.6.813. PMID 12810484. /wiki/Doi_(identifier) ↩

  62. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML (September 2011). "Treatable neurological disorders misdiagnosed as Creutzfeldt–Jakob disease". Annals of Neurology. 70 (3): 437–44. doi:10.1002/ana.22454. PMC 3170496. PMID 21674591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170496 ↩

  63. Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P (March 2021). "Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease". The Lancet. Neurology. 20 (3): 235–246. doi:10.1016/S1474-4422(20)30477-4. ISSN 1474-4465. PMC 8285036. PMID 33609480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285036 ↩

  64. Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P (March 2021). "Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease". The Lancet. Neurology. 20 (3): 235–246. doi:10.1016/S1474-4422(20)30477-4. ISSN 1474-4465. PMC 8285036. PMID 33609480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285036 ↩

  65. Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P (March 2021). "Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease". The Lancet. Neurology. 20 (3): 235–246. doi:10.1016/S1474-4422(20)30477-4. ISSN 1474-4465. PMC 8285036. PMID 33609480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285036 ↩

  66. Zerr I (7 April 2022). "Laboratory Diagnosis of Creutzfeldt–Jakob Disease". New England Journal of Medicine. 386 (14): 1345–1350. doi:10.1056/NEJMra2119323. PMID 35388668. /wiki/Doi_(identifier) ↩

  67. Park HY, Kim M, Suh CH, Kim SY, Shim WH, Kim SJ (December 2021). "Diagnostic value of diffusion-weighted brain magnetic resonance imaging in patients with sporadic Creutzfeldt-Jakob disease: a systematic review and meta-analysis". European Radiology. 31 (12): 9073–9085. doi:10.1007/s00330-021-08031-4. PMID 33982159. /wiki/Doi_(identifier) ↩

  68. Zerr I (7 April 2022). "Laboratory Diagnosis of Creutzfeldt–Jakob Disease". New England Journal of Medicine. 386 (14): 1345–1350. doi:10.1056/NEJMra2119323. PMID 35388668. /wiki/Doi_(identifier) ↩

  69. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (August 2006). "CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease". Neurology. 67 (4): 637–43. doi:10.1212/01.wnl.0000230159.67128.00. PMID 16924018. S2CID 23306766. /wiki/Doi_(identifier) ↩

  70. Tattum MH, Jones S, Pal S, Khalili-Shirazi A, Collinge J, Jackson GS (December 2010). "A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K" (PDF). Transfusion (Submitted manuscript). 50 (12): 2619–27. doi:10.1111/j.1537-2995.2010.02731.x. PMID 20561299. S2CID 33032755. http://discovery.ucl.ac.uk/146121/1/Tattum_et_al_A_highly_sensitive_immunoassay_for_the_detection_of_prion_infected_ELISA.pdf ↩

  71. Fragoso DC, Gonçalves Filho AL, Pacheco FT, Barros BR, Aguiar Littig I, Nunes RH, Maia Júnior AC, da Rocha AJ (2017-01-01). "Imaging of Creutzfeldt–Jakob Disease: Imaging Patterns and Their Differential Diagnosis". Radiographics. 37 (1): 234–257. doi:10.1148/rg.2017160075. PMID 28076012. /wiki/Doi_(identifier) ↩

  72. Finkenstaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, Weber T (June 1996). "MR imaging of Creutzfeldt–Jakob disease". Radiology. 199 (3): 793–8. doi:10.1148/radiology.199.3.8638007. PMID 8638007. /wiki/Doi_(identifier) ↩

  73. Ukisu R, Kushihashi T, Kitanosono T, Fujisawa H, Takenaka H, Ohgiya Y, Gokan T, Munechika H (February 2005). "Serial diffusion-weighted MRI of Creutzfeldt–Jakob disease". AJR. American Journal of Roentgenology. 184 (2): 560–6. doi:10.2214/ajr.184.2.01840560. PMID 15671380. /wiki/Doi_(identifier) ↩

  74. Kumaran SP, Gupta K, Pushpa BT, Viswamitra S, Joshy EV (2012). "Diffusion-weighted imaging: As the first diagnostic clue to Creutzfeldt Jacob [sic] disease". Journal of Neurosciences in Rural Practice. 3 (3): 408–410. doi:10.4103/0976-3147.102645. ISSN 0976-3147. PMC 3505356. PMID 23189017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505356 ↩

  75. Abdulmassih R, Min Z (March 2016). "An ominous radiographic feature: cortical ribbon sign". Internal and Emergency Medicine. 11 (2): 281–3. doi:10.1007/s11739-015-1287-4. PMID 26238299. https://doi.org/10.1007%2Fs11739-015-1287-4 ↩

  76. Tschampa HJ, Mürtz P, Flacke S, Paus S, Schild HH, Urbach H (May 2003). "Thalamic involvement in sporadic Creutzfeldt–Jakob disease: a diffusion-weighted MR imaging study". AJNR. American Journal of Neuroradiology. 24 (5): 908–15. PMC 7975779. PMID 12748093. Archived from the original on 10 October 2008. http://www.ajnr.org/cgi/content/full/24/5/908 ↩

  77. Finkenstaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, Weber T (June 1996). "MR imaging of Creutzfeldt–Jakob disease". Radiology. 199 (3): 793–8. doi:10.1148/radiology.199.3.8638007. PMID 8638007. /wiki/Doi_(identifier) ↩

  78. Morley NC, Hofer M, Wilkinson P, Bradley KM (2021). "18FDG PET-CT in sporadic Creutzfeldt–Jakob disease, correlated with MRI and histology". World J Nucl Med. 20 (4): 411–413. doi:10.4103/wjnm.wjnm_5_21. PMC 8686746. PMID 35018165. S2CID 244465297. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686746 ↩

  79. Connor A, Wang H, Appleby BS, Rhoads DD (2019-09-24). "Clinical Laboratory Tests Used To Aid in Diagnosis of Human Prion Disease". Journal of Clinical Microbiology. 57 (10): e00769–19. doi:10.1128/JCM.00769-19. ISSN 0095-1137. PMC 6760952. PMID 31366689. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760952 ↩

  80. Igel-Egalon A, Béringue V, Rezaei H, Sibille P (2018). "Prion Strains and Transmission Barrier Phenomena". Pathogens. 7 (1): 5. doi:10.3390/pathogens7010005. ISSN 2076-0817. PMC 5874731. PMID 29301257. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874731 ↩

  81. Sternberg's Diagnostic Surgical Pathology, 5th edition. ↩

  82. Liberski, P.P. (2004). "Spongiform change – an electron microscopic view". Folia Neuropathologica. 42, suppl B: 59–70. PMID 16903142. /wiki/PMID_(identifier) ↩

  83. "Pathology of Degenerative CNS Diseases". library.med.utah.edu. http://library.med.utah.edu/WebPath/TUTORIAL/CNS/CNSDG.html ↩

  84. G B D, Kumar A, C M M, M M A, H B P, S K M (2012-08-14). "Transmissible Spongiform Encephalopathies Affecting Humans". ISRN Infectious Diseases. 2013: 1–11. doi:10.5402/2013/387925. https://doi.org/10.5402%2F2013%2F387925 ↩

  85. Sternberg's Diagnostic Surgical Pathology, 5th edition. ↩

  86. Budka H, Will RG (12 November 2015). "The end of the BSE saga: do we still need surveillance for human prion diseases?" (PDF). Swiss Medical Weekly. 145: w14212. doi:10.4414/smw.2015.14212. PMID 26715203. http://www.zora.uzh.ch/id/eprint/115870/1/smw-2015-14212.pdf ↩

  87. Ridley RM, Baker HF, Crow TJ (February 1986). "Transmissible and non-transmissible neurodegenerative disease: similarities in age of onset and genetics in relation to aetiology". Psychological Medicine. 16 (1): 199–207. doi:10.1017/s0033291700002634. PMID 3961045. S2CID 38449324. /wiki/Doi_(identifier) ↩

  88. "who.int: "Fact sheets no 180: Variant Creutzfeldt–Jakob disease" Feb 2012 ed". Archived from the original on February 4, 2016. https://web.archive.org/web/20160204002108/http://www.who.int/mediacentre/factsheets/fs180/en/ ↩

  89. Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P (March 2021). "Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease". The Lancet. Neurology. 20 (3): 235–246. doi:10.1016/S1474-4422(20)30477-4. ISSN 1474-4465. PMC 8285036. PMID 33609480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285036 ↩

  90. Krasnianski A (2006-09-01). "Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD". Brain. 129 (9): 2288–2296. doi:10.1093/brain/awl123. ISSN 0006-8950. PMID 16720682. https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awl123 ↩

  91. Liao J, Hu W, Chen S, Huang C, Dong S, Chen W, Chen X, Chen L (2024-04-09). "Multidimensional features of sporadic Creutzfeldt-Jakob disease in the elderly: a case report and systematic review". Frontiers in Aging Neuroscience. 16. doi:10.3389/fnagi.2024.1379011. ISSN 1663-4365. PMC 11035806. PMID 38655431. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035806 ↩

  92. Krasnianski A (2006-09-01). "Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD". Brain. 129 (9): 2288–2296. doi:10.1093/brain/awl123. ISSN 0006-8950. PMID 16720682. https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awl123 ↩

  93. Jurcau MC, Jurcau A, Diaconu RG, Hogea VO, Nunkoo VS (2024-09-20). "A Systematic Review of Sporadic Creutzfeldt-Jakob Disease: Pathogenesis, Diagnosis, and Therapeutic Attempts". Neurology International. 16 (5): 1039–1065. doi:10.3390/neurolint16050079. ISSN 2035-8377. PMC 11417857. PMID 39311352. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417857 ↩

  94. Liao J, Hu W, Chen S, Huang C, Dong S, Chen W, Chen X, Chen L (2024-04-09). "Multidimensional features of sporadic Creutzfeldt-Jakob disease in the elderly: a case report and systematic review". Frontiers in Aging Neuroscience. 16. doi:10.3389/fnagi.2024.1379011. ISSN 1663-4365. PMC 11035806. PMID 38655431. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035806 ↩

  95. Glatzel M, Abela E, Maissen M, Aguzzi A (2003-11-06). "Extraneural Pathologic Prion Protein in Sporadic Creutzfeldt–Jakob Disease". New England Journal of Medicine. 349 (19): 1812–1820. doi:10.1056/NEJMoa030351. ISSN 0028-4793. PMID 14602879. http://www.nejm.org/doi/abs/10.1056/NEJMoa030351 ↩

  96. Budka H, Will RG (12 November 2015). "The end of the BSE saga: do we still need surveillance for human prion diseases?" (PDF). Swiss Medical Weekly. 145: w14212. doi:10.4414/smw.2015.14212. PMID 26715203. http://www.zora.uzh.ch/id/eprint/115870/1/smw-2015-14212.pdf ↩

  97. "who.int: "Fact sheets no 180: Variant Creutzfeldt–Jakob disease" Feb 2012 ed". Archived from the original on February 4, 2016. https://web.archive.org/web/20160204002108/http://www.who.int/mediacentre/factsheets/fs180/en/ ↩

  98. Budka H, Will RG (12 November 2015). "The end of the BSE saga: do we still need surveillance for human prion diseases?" (PDF). Swiss Medical Weekly. 145: w14212. doi:10.4414/smw.2015.14212. PMID 26715203. http://www.zora.uzh.ch/id/eprint/115870/1/smw-2015-14212.pdf ↩

  99. "who.int: "Fact sheets no 180: Variant Creutzfeldt–Jakob disease" Feb 2012 ed". Archived from the original on February 4, 2016. https://web.archive.org/web/20160204002108/http://www.who.int/mediacentre/factsheets/fs180/en/ ↩

  100. Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR, Onwuzulike K, Puoti G, Cohen ML, Schonberger LB, Cali I (July 2016). "Human prion diseases: surgical lessons learned from iatrogenic prion transmission". Neurosurgical Focus. 41 (1): E10. doi:10.3171/2016.5.FOCUS15126. PMC 5082740. PMID 27364252. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082740 ↩

  101. Budka H, Will RG (12 November 2015). "The end of the BSE saga: do we still need surveillance for human prion diseases?" (PDF). Swiss Medical Weekly. 145: w14212. doi:10.4414/smw.2015.14212. PMID 26715203. http://www.zora.uzh.ch/id/eprint/115870/1/smw-2015-14212.pdf ↩

  102. "Creutzfeldt–Jakob Disease Fact Sheet | National Institute of Neurological Disorders and Stroke". NINDS. March 2003. Archived from the original on 4 July 2017. Retrieved 16 July 2017. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet ↩

  103. Holmqvist J, Wikman A, Pedersen OB, Nielsen KR, Rostgaard K, Hjalgrim H, Edgren G (2020). "No evidence of transfusion transmitted sporadic Creutzfeldt-Jakob disease: results from a bi-national cohort study". Transfusion. 60 (4): 694–697. doi:10.1111/trf.15751. ISSN 0041-1132. PMID 32187687. Retrieved 2025-04-22. https://onlinelibrary.wiley.com/doi/10.1111/trf.15751 ↩

  104. Belay ED, Schonberger LB (December 2002). "Variant Creutzfeldt–Jakob disease and bovine spongiform encephalopathy". Clinics in Laboratory Medicine. 22 (4): 849–62, v–vi. doi:10.1016/S0272-2712(02)00024-0. PMID 12489284. /wiki/Doi_(identifier) ↩

  105. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A (November 2015). "Creutzfeldt–Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy". Neurosurgical Focus. 39 (5): E2. doi:10.3171/2015.8.FOCUS15328. PMID 26646926. https://doi.org/10.3171%2F2015.8.FOCUS15328 ↩

  106. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A (November 2015). "Creutzfeldt–Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy". Neurosurgical Focus. 39 (5): E2. doi:10.3171/2015.8.FOCUS15328. PMID 26646926. https://doi.org/10.3171%2F2015.8.FOCUS15328 ↩

  107. "Treatment". nhs.uk. 2017-10-23. Retrieved 2018-04-17. https://www.nhs.uk/conditions/creutzfeldt-jakob-disease-cjd/treatment/ ↩

  108. Ng MC, Westover MB, Cole AJ (2014-02-07). "Treating seizures in Creutzfeldt–Jakob disease". Epilepsy & Behavior Case Reports. 2: 75–9. doi:10.1016/j.ebcr.2014.01.004. PMC 4308028. PMID 25667875. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308028 ↩

  109. Mead S, Khalili-Shirazi A, Potter C, Mok T, Nihat A, Hyare H, Canning S, Schmidt C, Campbell T, Darwent L, Muirhead N, Ebsworth N, Hextall P, Wakeling M, Linehan J (2022-04-01). "Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme". The Lancet Neurology. 21 (4): 342–354. doi:10.1016/S1474-4422(22)00082-5. ISSN 1474-4422. PMID 35305340. https://www.thelancet.com/article/S1474-4422(22)00082-5/fulltext ↩

  110. Mizutani T, Okumura A, Oda M, Shiraki H (February 1981). "Panencephalopathic type of Creutzfeldt–Jakob disease: primary involvement of the cerebral white matter". Journal of Neurology, Neurosurgery, and Psychiatry. 44 (2): 103–15. doi:10.1136/jnnp.44.2.103. PMC 490840. PMID 7012278. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC490840 ↩

  111. "Belfast man with VCJD dies after long battle". BBC News. 7 March 2011. https://www.bbc.co.uk/news/uk-northern-ireland-12667709 ↩

  112. "CJD (Creutzfeldt–Jakob Disease, Classic)". Centers for Disease Control and Prevention. 2008-02-26. Archived from the original on 2009-05-06. Retrieved 2009-06-20. https://web.archive.org/web/20090506212244/http://www.cdc.gov/ncidod/dvrd/cjd/index.htm ↩

  113. "vCJD (Variant Creutzfeldt–Jakob Disease)". Centers for Disease Control and Prevention. 2007-01-04. Archived from the original on 2009-05-07. Retrieved 2009-06-20. https://web.archive.org/web/20090507193309/http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet_nvcjd.htm ↩

  114. CDC (2024-05-14). "Classic Creutzfeldt-Jakob Disease". Creutzfeldt-Jakob Disease (CJD). Retrieved 2025-05-14. https://www.cdc.gov/creutzfeldt-jakob/about/index.html ↩

  115. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (January 2020). "Creutzfeldt–Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation" (PDF). The Lancet. Infectious Diseases. 20 (1): e2 – e10. doi:10.1016/S1473-3099(19)30615-2. PMID 31876504. S2CID 209483271. Archived (PDF) from the original on 2022-10-09. http://eprints.whiterose.ac.uk/155256/9/CJD%20review_submitted%20to%20TLID%2013.09.19%20for%20WRR.pdf ↩

  116. "Occurrence and Transmission | Creutzfeldt–Jakob Disease, Classic (CJD) | Prion Disease | CDC". www.cdc.gov. 2019-05-08. Retrieved 2020-11-04. https://www.cdc.gov/prions/cjd/occurrence-transmission.html ↩

  117. Bosque P, Tyler K (2020). Prions and Prion Disease of the Central Nervous System (Transmissible Neurodegenerative Diseases). www.clinicalkey.com: Elsevier, Inc. pp. 2288–2300. https://www.clinicalkey.com/#!/content/book/3-s2.0-B978032348255400179X?scrollTo=#hl0000833 ↩

  118. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (January 2020). "Creutzfeldt–Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation" (PDF). The Lancet. Infectious Diseases. 20 (1): e2 – e10. doi:10.1016/S1473-3099(19)30615-2. PMID 31876504. S2CID 209483271. Archived (PDF) from the original on 2022-10-09. http://eprints.whiterose.ac.uk/155256/9/CJD%20review_submitted%20to%20TLID%2013.09.19%20for%20WRR.pdf ↩

  119. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (January 2020). "Creutzfeldt–Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation" (PDF). The Lancet. Infectious Diseases. 20 (1): e2 – e10. doi:10.1016/S1473-3099(19)30615-2. PMID 31876504. S2CID 209483271. Archived (PDF) from the original on 2022-10-09. http://eprints.whiterose.ac.uk/155256/9/CJD%20review_submitted%20to%20TLID%2013.09.19%20for%20WRR.pdf ↩

  120. Bosque P, Tyler K (2020). Prions and Prion Disease of the Central Nervous System (Transmissible Neurodegenerative Diseases). www.clinicalkey.com: Elsevier, Inc. pp. 2288–2300. https://www.clinicalkey.com/#!/content/book/3-s2.0-B978032348255400179X?scrollTo=#hl0000833 ↩

  121. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (January 2020). "Creutzfeldt–Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation" (PDF). The Lancet. Infectious Diseases. 20 (1): e2 – e10. doi:10.1016/S1473-3099(19)30615-2. PMID 31876504. S2CID 209483271. Archived (PDF) from the original on 2022-10-09. http://eprints.whiterose.ac.uk/155256/9/CJD%20review_submitted%20to%20TLID%2013.09.19%20for%20WRR.pdf ↩

  122. Ironside JW (1996). "Neuropathological diagnosis of human prion disease; morphological studies". In Baker HF, Ridley RM (eds.). Prion Diseases. Vol. 3. pp. 35–57. doi:10.1385/0896033422. ISBN 978-0-89603-342-9. 978-0-89603-342-9 ↩

  123. Meggendorfer F (1930). "Klinische und genealogische Beobachtungen bei einem Fall von spastischer Pseudokosklerose Jakobs". Zeitschrift für die Gesamte Neurologie und Psychiatrie. 128 (1–4): 337–41. doi:10.1007/bf02864269. S2CID 178922541. /wiki/Doi_(identifier) ↩

  124. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003). "Sporadic and familial CJD: classification and characterisation". British Medical Bulletin. 66: 213–39. doi:10.1093/bmb/66.1.213. PMID 14522861. https://doi.org/10.1093%2Fbmb%2F66.1.213 ↩

  125. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  126. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  127. Ae R, Hamaguchi T, Nakamura Y, Yamada M, Tsukamoto T, Mizusawa H, Belay ED, Schonberger LB (March 2018). "Update: Dura Mater Graft-Associated Creutzfeldt–Jakob Disease - Japan, 1975-2017". MMWR. Morbidity and Mortality Weekly Report. 67 (9): 274–278. doi:10.15585/mmwr.mm6709a3. PMC 5844283. PMID 29518068. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844283 ↩

  128. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  129. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  130. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  131. "The Nobel Prize in Physiology or Medicine 1997: Stanley B. Prusiner". NobelPrize.org. Archived from the original on 2011-02-20. Retrieved 2011-02-21. https://www.nobelprize.org/nobel_prizes/medicine/laureates/1997/ ↩

  132. Manuelidis L, Yu ZX, Barquero N, Banquero N, Mullins B (February 2007). "Cells infected with scrapie and Creutzfeldt–Jakob disease agents produce intracellular 25-nm virus-like particles". Proceedings of the National Academy of Sciences of the United States of America. 104 (6): 1965–70. Bibcode:2007PNAS..104.1965M. doi:10.1073/pnas.0610999104. PMC 1794316. PMID 17267596. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794316 ↩

  133. Creutzfeldt–Jakob Disease (CJD) – the facts. Infectious Diseases Epidemiology & Surveillance – Department of Health, Victoria, Australia Archived 2015-06-28 at the Wayback Machine http://ideas.health.vic.gov.au/diseases/cjd-facts.asp ↩

  134. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S (1997). "Is Creutzfeldt–Jakob disease transmitted in blood?". Emerging Infectious Diseases. 3 (2): 155–63. doi:10.3201/eid0302.970208. PMC 2627622. PMID 9204296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627622 ↩

  135. "Mad cow link in hunter's death". Stuff. 16 November 2012. https://www.stuff.co.nz/national/7962582/Mad-cow-link-in-hunters-death ↩

  136. via Bloomberg News, "Mike Homer dies at 50; a former vice president of Netscape", Los Angeles Times, February 5, 2009. Accessed February 6, 2009. /wiki/Bloomberg_News ↩

  137. Plett B, Hammami R, Rabbani M, Chris T, John T. "Remembering Graham Usher". Jadaliyya. Retrieved 11 March 2025. https://www.jadaliyya.com/Details/29938 ↩

  138. "Autopsy confirms rare brain disease in NH patient". MyFoxBoston. 2013-09-20. Archived from the original on 21 September 2013. Retrieved 20 September 2013. http://www.myfoxboston.com/story/23489308/2013/09/20/autopsy-confirms-rare-brain-disease-in-nh-patient ↩

  139. "NH Patient Likely Died of Rare Brain Disease". The Big Story. AP. Archived from the original on 8 September 2013. Retrieved 5 September 2013. http://bigstory.ap.org/article/surgical-gear-quarantined-over-rare-brain-disease ↩

  140. Kowalczyk L. "5 patients at Cape hospital at risk for rare brain disease". Boston Globe. Archived from the original on 9 September 2013. Retrieved 25 November 2013. https://web.archive.org/web/20130909210818/http://www.boston.com/news/local/massachusetts/2013/09/05/cape-cod-hospital-patients-possibly-exposed-brain-disease/CwGauqzFxf6Om8agTvUoAJ/story.html ↩

  141. Herald KH. "Officials: Lockhart, 'Utah's Iron Lady' died from Creutzfeldt–Jakob disease". Daily Herald. Archived from the original on 2015-01-20. Retrieved 2015-01-18. http://www.heraldextra.com/news/local/central/provo/officials-lockhart-died-from-creutzfeldt-jakob-disease/article_ab2ba7d7-26b0-5e7a-8347-3142e5ded8cc.html ↩

  142. Schudel M (June 14, 2015). "John S. Carroll, acclaimed newspaper editor in Baltimore and L.A., dies at 73". The Washington Post. Archived from the original on September 19, 2016. https://www.washingtonpost.com/national/john-s-carroll-edited-newspapers-in-baltimore-and-los-angeles-dies-at-73/2015/06/14/65bd5c1a-eac7-11e4-9a6a-c1ab95a0600b_story.html ↩

  143. "Barbara Tarbuck, 'General Hospital' and 'American Horror Story' Actress, Dies at 74". 2016-12-30. Archived from the original on 2016-12-30. Retrieved 2016-12-30. https://variety.com/2016/tv/news/barbara-tarbuck-dead-dies-general-hospital-jane-jacks-ahs-1201950002/ ↩

  144. "José Baselga, renowned cancer researcher and AstraZeneca oncology R&D head, dies at 61". statnews.com. Stat News. 21 March 2021. https://www.statnews.com/2021/03/21/jose-baselga-astrazeneca-renowned-cancer-researcher-dies-at-61/ ↩

  145. Trout J, Roberts M, Tabet M, Kotkowski E, Horn S (2024-04-09). "Two Hunters from the Same Lodge Afflicted with sporadic CJD: Is Chronic Wasting Disease to Blame? (P7-13.002)". Neurology. 102 (17_supplement_1). doi:10.1212/WNL.0000000000204407. ISSN 0028-3878. https://www.neurology.org/doi/10.1212/WNL.0000000000204407 ↩

  146. "Detecting Prions in Blood" (PDF). Microbiology Today: 195. August 2010. Archived from the original (PDF) on 31 March 2012. Retrieved 2011-08-21. https://web.archive.org/web/20120331021750/https://www.sgm.ac.uk/pubs/micro_today/pdf/081010.pdf ↩

  147. Rubenstein R, Chang B, Gray P, Piltch M, Bulgin MS, Sorensen-Melson S, Miller MW (July 2010). "A novel method for preclinical detection of PrPSc in blood". The Journal of General Virology. 91 (Pt 7): 1883–92. doi:10.1099/vir.0.020164-0. PMID 20357038. https://doi.org/10.1099%2Fvir.0.020164-0 ↩

  148. Orrú CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman BR, Fiorini M, Pocchiari M, Monaco S, Caughey B, Zanusso G (August 2014). "A test for Creutzfeldt–Jakob disease using nasal brushings". The New England Journal of Medicine. 371 (6): 519–29. doi:10.1056/NEJMoa1315200. PMC 4186748. PMID 25099576. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186748 ↩

  149. Bone I (12 July 2006). "Intraventricular Pentosan Polysulphate in Human Prion Diseases: A study of Experience in the United Kingdom". Medical Research Council. Archived from the original on 3 November 2012. Retrieved 2012-11-09. https://www.bbc.co.uk/news/uk-northern-ireland-12667709 ↩

  150. "Use of Pentosan Polysulphate in the treatment of, or prevention of, vCJD". Department of Health:CJD Therapy Advisory Group. Archived from the original on 2007-07-05. Retrieved 2007-10-30. http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/CJD/CJDgeneralinformation/DH_4031039 ↩

  151. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K (May 2007). "Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?". Expert Opinion on Biological Therapy. 7 (5): 713–26. doi:10.1517/14712598.7.5.713. PMID 17477808. S2CID 12725001. /wiki/Expert_Opinion_on_Biological_Therapy ↩

  152. "The rise and fall of pentosan polysulfate in prion disease". www.cureffi.org. Retrieved 2022-05-09. https://www.cureffi.org/2012/12/13/the-rise-and-fall-of-pentosan-polysulfate-in-prion-disease/ ↩

  153. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H (December 2006). "Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice". The Journal of Clinical Investigation. 116 (12): 3204–10. doi:10.1172/JCI29236. PMC 1679709. PMID 17143329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1679709 ↩

  154. "Revamp of brain 'could slow CJD'". news.bbc.co.uk. BBC News. 2006-12-04. Retrieved 25 September 2022. http://news.bbc.co.uk/1/hi/health/6198072.stm ↩

  155. Gambetti P. "Creutzfeldt–Jakob Disease (CJD)". The Merck Manuals: Online Medical Library. Archived from the original on 2011-06-04. Retrieved 2011-06-04. http://www.merckmanuals.com/home/sec06/ch090/ch090b.html ↩

  156. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J (April 2009). "Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial". The Lancet. Neurology. 8 (4): 334–44. doi:10.1016/S1474-4422(09)70049-3. PMC 2660392. PMID 19278902. /wiki/Martin_Rossor ↩

  157. Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, Fallahi M, Hodder P, Weissmann C, Lasmézas CI (April 2013). "Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents". Proceedings of the National Academy of Sciences of the United States of America. 110 (17): 7044–9. Bibcode:2013PNAS..110.7044K. doi:10.1073/pnas.1303510110. PMC 3637718. PMID 23576755. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637718 ↩

  158. Mead S, Khalili-Shirazi A, Potter C, Mok T, Nihat A, Hyare H, Canning S, Schmidt C, Campbell T, Darwent L, Muirhead N, Ebsworth N, Hextall P, Wakeling M, Linehan J, Libri V, Williams B, Jaunmuktane Z, Brandner S, Rudge P, Collinge J (2022). "Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: Evaluation of a first-in-human treatment programme". The Lancet Neurology. 21 (4): 342–354. doi:10.1016/S1474-4422(22)00082-5. PMID 35305340. S2CID 247479825. https://discovery.ucl.ac.uk/id/eprint/10145671/ ↩